How big is the Antibody-drug Conjugates Market?

The Antibody-drug Conjugates Market size is expected to reach USD 12.05 billion in 2024 and grow at a CAGR of 29.57% to reach USD 44.05 billion by 2029. Read More

What is the current Antibody-drug Conjugates Market size?

In 2024, the Antibody-drug Conjugates Market size is expected to reach USD 12.05 billion. Read More

Who are the key players in Antibody-drug Conjugates Market?

Seagen Inc., F Hoffmann-La Roche Ltd, Pfizer Inc, AstraZeneca and Gilead Sciences, Inc are the major companies operating in the Antibody-drug Conjugates Market. Read More

Which is the fastest growing region in Antibody-drug Conjugates Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Antibody-drug Conjugates Market?

In 2024, the North America accounts for the largest market share in Antibody-drug Conjugates Market. Read More

What years does this Antibody-drug Conjugates Market cover, and what was the market size in 2023?

In 2023, the Antibody-drug Conjugates Market size was estimated at USD 8.49 billion. The report covers the Antibody-drug Conjugates Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Antibody-drug Conjugates Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

What are the emerging technologies impacting the Antibody Drug Conjugates Market?

The emerging technologies impacting the Antibody Drug Conjugates Market are a) AI-powered drug design b) Next-generation linker technologies c) Targeted delivery systems Read More

Antibody Drug Conjugates Market Share

Statistics for the 2023 & 2024 Antibody Drug Conjugates market share, created by Mordor Intelligence™ Industry Reports. Antibody Drug Conjugates share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Antibody Drug Conjugates Industry

The antibody drug conjugates market is slightly fragmented in nature and competitive due to the presence of several companies across the globe. The competitive landscape includes an analysis of international, local and top ADC companies, that hold major market shares, including Seagen Inc., ImmunoGen Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, AbbVie Inc., AstraZeneca PLC, Gilead Sciences Inc, and others.